NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis $24.27 -0.02 (-0.08%) Closing price 04:00 PM EasternExtended Trading$24.04 -0.23 (-0.97%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CPRX alerts:Sign Up Key Stats Today's Range$23.81▼$24.6550-Day Range$20.58▼$25.7452-Week Range$14.47▼$26.16Volume1.06 million shsAverage Volume1.11 million shsMarket Capitalization$2.96 billionP/E Ratio20.57Dividend YieldN/APrice Target$32.29Consensus RatingBuy Company OverviewCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Read More… Catalyst Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreCPRX MarketRank™: Catalyst Pharmaceuticals scored higher than 94% of companies evaluated by MarketBeat, and ranked 87th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCatalyst Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Catalyst Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth12.11% Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 12.11% in the coming year, from $1.90 to $2.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 20.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 20.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.51.Price to Earnings Growth RatioCatalyst Pharmaceuticals has a PEG Ratio of 3.31. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 7.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Catalyst Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.34% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently decreased by 1.77%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-1.99 Percentage of Shares Shorted7.34% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently decreased by 1.77%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment1.31 News SentimentCatalyst Pharmaceuticals has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Catalyst Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 7 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,439,095.00 in company stock.Percentage Held by Insiders10.40% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Catalyst Pharmaceuticals' insider trading history. Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Stock News HeadlinesIs Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?April 30 at 5:32 PM | finance.yahoo.comCatalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025April 30 at 8:03 AM | globenewswire.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 1, 2025 | Brownstone Research (Ad)Catalyst Pharmaceuticals, Inc. (CPRX): Among Stocks with Consistent Growth to Buy NowApril 27, 2025 | msn.comCatalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025April 22, 2025 | globenewswire.comCatalyst Pharmaceuticals price target raised to $34 from $33 at BofAApril 22, 2025 | markets.businessinsider.comCiti Remains a Buy on Catalyst Pharma (CPRX)April 18, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gainsApril 17, 2025 | marketwatch.comSee More Headlines CPRX Stock Analysis - Frequently Asked Questions How have CPRX shares performed this year? Catalyst Pharmaceuticals' stock was trading at $20.87 at the beginning of 2025. Since then, CPRX shares have increased by 16.3% and is now trading at $24.27. View the best growth stocks for 2025 here. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, meeting analysts' consensus estimates of $0.10. The biopharmaceutical company had revenue of $35.95 million for the quarter, compared to analysts' expectations of $34.47 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 40.79% and a net margin of 31.01%. Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' top institutional investors include Bank of New York Mellon Corp (0.58%), Principal Financial Group Inc. (0.51%), Rhumbline Advisers (0.26%) and Moody Aldrich Partners LLC (0.15%). Insiders that own company stock include Patrick J Mcenany, Steve Miller, David S Tierney, Donald A Denkhaus, Richard J Daly, Brian Elsbernd, Philip H Coelho, Gary Ingenito, Alicia Grande, Carmen Jeffrey Del, Preethi Sundaram and Molly Harper. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings11/09/2021Today5/01/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CPRX CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees80Year Founded2002Price Target and Rating Average Stock Price Target$32.29 High Stock Price Target$36.00 Low Stock Price Target$29.00 Potential Upside/Downside+32.9%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$1.31 Trailing P/E Ratio20.59 Forward P/E Ratio12.78 P/E Growth3.31Net Income$71.41 million Net Margins31.01% Pretax Margin41.00% Return on Equity40.79% Return on Assets34.87% Debt Debt-to-Equity RatioN/A Current Ratio5.11 Quick Ratio4.92 Sales & Book Value Annual Sales$491.73 million Price / Sales6.02 Cash Flow$2.27 per share Price / Cash Flow10.72 Book Value$3.30 per share Price / Book7.36Miscellaneous Outstanding Shares121,959,000Free Float106,153,000Market Cap$2.96 billion OptionableOptionable Beta0.79 Social Links Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CPRX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.